Literature DB >> 21641051

Galectin-3 in heart failure: high levels are associated with all-cause mortality.

Thor Ueland, Pål Aukrust, Kaspar Broch, Svend Aakhus, Rita Skårdal, Pieter Muntendam, Lars Gullestad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21641051     DOI： 10.1016/j.ijcard.2011.05.081

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  23 in total

Review 1.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

2.  Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

Authors:  G Michael Felker; Mona Fiuzat; Linda K Shaw; Robert Clare; David J Whellan; Luca Bettari; Shailesh C Shirolkar; Mark Donahue; Dalane W Kitzman; Faiez Zannad; Ileana L Piña; Christopher M O'Connor
Journal:  Circ Heart Fail       Date:  2011-10-20       Impact factor: 8.790

Review 3.  Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.

Authors:  Francisco Javier Carrasco-Sánchez; María Inmaculada Páez-Rubio
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

Review 4.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

5.  Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

Authors:  Omar F AbouEzzeddine; Phillip Haines; Susanna Stevens; Jose Nativi-Nicolau; G Michael Felker; Barry A Borlaug; Horng H Chen; Russell P Tracy; Eugene Braunwald; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2015-03       Impact factor: 12.035

Review 6.  Cardiovascular biomarkers and sex: the case for women.

Authors:  Lori B Daniels; Alan S Maisel
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

7.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.

Authors:  Jennifer E Ho; Chunyu Liu; Asya Lyass; Paul Courchesne; Michael J Pencina; Ramachandran S Vasan; Martin G Larson; Daniel Levy
Journal:  J Am Coll Cardiol       Date:  2012-08-29       Impact factor: 24.094

8.  Plasma galectin 3 and heart failure risk in the Physicians' Health Study.

Authors:  Luc Djoussé; Chisa Matsumoto; Andrew Petrone; Natalie L Weir; Michael Y Tsai; J Michael Gaziano
Journal:  Eur J Heart Fail       Date:  2013-12-04       Impact factor: 15.534

9.  Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.

Authors:  Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola
Journal:  J Card Fail       Date:  2015-11-10       Impact factor: 5.712

10.  Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.

Authors:  Dirk J Lok; Sjoukje I Lok; Pieta W Bruggink-André de la Porte; Erik Badings; Eric Lipsic; Jan van Wijngaarden; Rudolf A de Boer; Dirk J van Veldhuisen; Peter van der Meer
Journal:  Clin Res Cardiol       Date:  2012-08-12       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.